Cosmos Health与Libytec达成Pathmuscle药物生产协议,五年产量预计超120万单位

美股速递
Jan 05

Cosmos Health Inc(简称:Cosmos Health)近日宣布与Libytec公司签署了一项关于Pathmuscle药物的生产合作协议。根据协议条款,双方将在未来五年内合作生产该药物,预计总产量将突破120万单位。

这一合作标志着Cosmos Health在医药制造领域的进一步拓展,同时也为Pathmuscle药物的市场供应提供了稳定保障。双方均对此次合作充满信心,预计该协议将带来显著的经济效益和市场影响力。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10